Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Share News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

e-Therapeutics pleases with pipeline progress

Tue, 14th May 2013 09:46

News from biotech company e-Therapeutics about the progress of two clinical trials for its cancer drug pleased the markets on Tuesday. The AIM-listed company provided first findings for the company's ETS2101 drug candidate in Phase I trials in the US for patients with brain cancer and in the UK for patients with solid tumours.Initial data from trials, where 12 patients have been enrolled so far, showed a decrease in tumour size for one patient with an "untreatable" tumour, while no serious adverse events have been attributed to the drug so far.The company, which in February raised £40m to fund its clinical developments, unveiled its preliminary results for the year to January 31st where net losses of £4.2m were slightly better than forecasts, but £1.0m higher than the previous year due to the company's increasing investment in drug discovery and development.E-Therapeutics, which discovers new medicines using its proprietary 'network pharmacology' computer technology, said it expects key Phase I results from the US trials for brain cancer in the third quarter of the year and those for UK trials for solid tumours in the early 2014. Chief Financial Officer Dr Daniel Elger said the company was increasing investment in research and development. "Our recent £40m fundraising leaves us even better placed to pursue our goals, with a cash runway that now extends to a potential partnering deal for our lead cancer drug and resources sufficient to generate a diversified portfolio of assets over the next three-four years."House broker Panmure Gordon was excited to hear about the "strong success" in early stages of the trial."This sector is not used to success so the pessimists will scream sample size, chance event and other such instruments of caution," admitted analyst Savvas Neophytou. "They would be right from a purist point of view but the fact remains one particular patient who had ran out of all therapeutic options is still alive as a result of ETS2101 and that is a significant achievement for the company's first shot at goal." He said he believed this news mitigated development risk in E-Therapeutics and so he reducing the project's discount rate to 18%, from 20% previously.Shares in e-Therapeutics were up 8.0% at 33.60p at 13:41 on Tuesday.OH
More News
16 Oct 2013 11:57

UK WINNERS & LOSERS: Hargreaves Continues To Rise, e-Therapeutics Trips

Read more
16 Oct 2013 08:56

e-Therapeutics Pretax Loss Widens As R&D Expenditure Rises

Read more
30 Sep 2013 18:45

DIRECTOR DEALINGS: E-Therapeutics Exec, Wife Combined Shares Total 1.8M

Read more
24 Jul 2013 15:53

Wife of DS Smith CEO sells 5.6m-pound stake

The wife of DS Smith frontman Miles Roberts sold a substantial sum of shares in the packaging and office supplies firm on the same day it was revealed the Chief Executive Officer (CEO) received a big pay increase last year. The move came on Tuesday, the same day DS Smith released its annual report

Read more
14 May 2013 08:04

Tuesday broker round-up UPDATE

Babcock International: Jefferies increases target price from 1080p to 1250p and maintains a buy recommendation. Barratt Developments: Bank of America takes target price from 265p to 325p, while downgrading to neutral. Belgravium Technologies: WH Ireland places both its target price and its neutral

Read more
10 May 2013 07:14

Friday broker round-up UPDATE

Afren: Westhouse Securities initiates with a target price of 160p and a buy recommendation. Ashmore Group: Credit Suisse raises target price from 375p to 440p upgrading from underperform to neutral. Barratt Developments: Citigroup increases target price from 245p to 315p leaving its neutral rating

Read more
19 Feb 2013 16:21

Debenhams Executive Director adds to stake

Michael Sharp, the Executive Director of retail chain Debenhams, has topped up his stake in the group with the purchase of 50,000 shares. Sharp, who has been in his current role since September 2011, bought the shares at 97.20p for a total of £48,598. He now holds 6.2m shares in the company. Debe

Read more
11 Feb 2013 09:15

e-Therapeutics shares jump following 40m equity issue

Drug discovery and development company e-Therapeutics is proposing to raise 40m pounds through an issue of new ordinary shares to existing and new institutional investors. The new shares will be priced at 32p, a premium of 4.0% to the closing mid-market price on Friday. Following the proposed issu

Read more
23 Oct 2012 09:23

Tuesday broker round-up

Aggreko: UBS cuts target from 2,750p to 2,550p, buy rating kept. ARM Holdings: Investec keeps buy rating and 800p target. Avacta: Panmure Gordon keeps buy rating and 1.75p target. AZ Electronic: Canaccord Genuity ups target from 360p to 376p, buy rating kept. Babcock: JPMorgan Cazenove ups targe

Read more
22 Oct 2012 08:19

Monday broker round-up - UPDATE

888 Holdings: Morgan Stanley ups target from 125p to 130p, overweight rating kept. Aggreko: Jefferies cuts target from 2,800p to 2,535p, buy rating kept; HSBC downgrades to underweight, target cut from 2,350p to 1,750p; JPMorgan Cazenove cuts target from 2,360p to 2,165p, neutral rating kept; Barcl

Read more
22 Oct 2012 07:53

e-therapeutics produces mixed interims

e-therapeutics, a drug discovery and development company, produced mixed interims with slightly increased losses, but reported progress on its lead cancer drug. As expected, first half losses increased to £1.8m (2011: loss of £1.5m), reflecting increased investment in the business. The company ha

Read more
15 Mar 2011 17:05

Bramson vehicle buys more shares in F&C

F&C Asset Management chairman Edward Bramson's investment vehicle SIGA LP has acquired more shares in the asset management company. Bramson was appointed chairman of F&C last month after a shareholder coup removed the previous incumbent, along with another non-executive, and appointed three new di

Read more
14 Mar 2011 17:19

Wife of outgoing FD sells British Land shares

Diane Roberts, the wife of British Land finance director Graham Roberts, has raised more than £1m by selling more than three-quarters of the couple's stake in the property investor. She sold 191,780 shares at 562.8p each, which raised £1.08m. The couple are left with 50,464 shares in British Land.

Read more
4 Mar 2011 17:03

Shaftesbury boss invests £100,000

Shaftesbury chief executive Jonathan Lane has invested a further £100,000 in the property investor. Lane has bought 22,222 shares at 450p each. That takes his stake to 966,233 shares, which is worth £4.3m at the latest purchase price. Lane raised just over £99,000 from the sale of option shares la

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.